Study for leftover cancer DNA in HER2-positive early breast cancer
Part of Cancer clinical trials.
This study looks for tiny traces of cancer after treatment by testing blood for “ctDNA,” which is leftover cancer DNA. It includes people with HER2-positive early breast cancer who are getting chemotherapy before surgery to see if this blood test can detect signs of remaining disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 20 years old when you join
- Have HER2-positive invasive breast cancer confirmed by pathology
- Plan to get chemotherapy before surgery (neoadjuvant chemotherapy, then surgery)
- Have clinical stage IIA through IIIC breast cancer
- Know your hormone receptor test result (hormone receptor status)
- Be able to sign informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a blood test (ctDNA) can help doctors monitor how well chemotherapy before surgery is working in women with HER2-positive breast cancer. It aims to see if changes in the blood can predict treatment success.
This study looks at leftover breast cancer cells (after chemo and targeted therapy) to find out why some cells resist treatment. It may help doctors better understand how to treat HER2-positive breast cancer in the future.
This trial is testing whether monitoring ctDNA (genetic material from the tumor in your blood) can help guide treatment for HER2-positive breast cancer before surgery. It is for people with early-stage (Stage II or III) disease who have not yet started treatment.
This trial looks at tumor DNA in the blood of people with a certain type of advanced breast cancer called HER2-low. The goal is to learn more about this cancer and how it changes over time, which may help guide future treatments.
This study looks at whether some people with stage 1 HER2-positive or “triple-negative” breast cancer may safely need less (de-escalated) chemotherapy after surgery. The goal is to keep the cancer risk low while reducing treatment intensity, using special blood testing over time.
This study tests a new blood test to see if it can find tiny bits of tumor DNA after chemotherapy. If you have a larger or higher-risk breast cancer and are getting chemotherapy before surgery, you may join. The test could help doctors know if your cancer is gone or if more treatment is needed.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.